ADP-520
Hematological malignancies, acute myeloid leukemia (AML), lymphoma, renal cell carcinoma (RCC) (indications that express CD70)
Indication-EnablingActive
Key Facts
Indication
Hematological malignancies, acute myeloid leukemia (AML), lymphoma, renal cell carcinoma (RCC) (indications that express CD70)
Phase
Indication-Enabling
Status
Active
Company
About Adaptimmune Therapeutics
Adaptimmune is a UK-based biotech focused on developing novel TCR T-cell therapies for cancer. The company recently underwent significant strategic changes, including the sale of its TECELRA, lete-cel, afami-cel, and uza-cel programs to US WorldMeds, delisting from Nasdaq, and a leadership overhaul. Its current strategy centers on advancing its earlier-stage PRAME and CD70-targeting programs while reducing operational costs as a private entity.
View full company profile